Characterizing Safety and Clinical Outcomes Associated with High-Dose Micafungin Utilization in Patients with Proven Invasive Candidiasis

Micafungin is the empiric antifungal agent of choice for the treatment of invasive candidiasis (IC). Pathophysiologic changes that occur in obese and/or critically ill patients can alter micafungin serum concentrations and the probability of target attainment. Although high doses of micafungin have...

Descripción completa

Detalles Bibliográficos
Autores principales: Grant, Victoria C., Nguyen, Kenneth, Rodriguez, Sasha, Zhou, Anna Y., Abdul-Mutakabbir, Jacinda C., Tan, Karen K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878997/
https://www.ncbi.nlm.nih.gov/pubmed/35202218
http://dx.doi.org/10.3390/tropicalmed7020023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878997/
https://www.ncbi.nlm.nih.gov/pubmed/35202218
http://dx.doi.org/10.3390/tropicalmed7020023

Ejemplares similares